Needham Downgrades Heron Therapeutics (HRTX) to Hold Jun 2, 2026 04:00PM
Heron Therapeutics loses patent case for CINVANTI drug Jun 2, 2026 08:12AM
Heron Therapeutics (HRTX) PT Lowered to $4 at H.C. Wainwright May 12, 2026 06:55AM
Heron Therapeutics (HRTX) Misses Q1 EPS by 2c ; Offers Guidance May 11, 2026 08:06AM
Heron Therapeutics reports Q4 2025 revenue of $40.5 million Jan 9, 2026 11:29AM


Dec 4, 2025 08:15AM Heron's APONVIE included in new postoperative nausea guidelines
Nov 4, 2025 03:40PM Heron Therapeutics (HRTX) PT Lowered to $5 at Jefferies
Nov 4, 2025 08:10AM Heron Therapeutics (HRTX) Misses Q3 EPS by 9c
Aug 15, 2025 07:45AM Heron Therapeutics adopts rights plan to protect $1.37 billion NOL assets
Aug 8, 2025 09:33AM Heron Therapeutics (HRTX) Misses Q2 EPS by 1c
Aug 8, 2025 07:45AM Heron Therapeutics completes $212.7 million capital restructuring
May 6, 2025 08:04AM Heron Therapeutics (HRTX) Tops Q1 EPS by 3c
May 6, 2025 07:31AM Heron Therapeutics (HRTX) Announces Settlement with Mylan Related to CINVANTI and APONVIE Patent Litigations
Feb 27, 2025 07:54AM Heron Therapeutics (HRTX) Tops Q4 EPS by 5c, provides guidance
Dec 3, 2024 04:43PM Heron Therapeutics (HRTX) Announces US District Court Upheld Validity of CINVANTI Patents
Nov 12, 2024 04:35PM Heron Therapeutics (HRTX) Tops Q3 EPS by 1c
Sep 25, 2024 08:02AM Heron Therapeutics (HRTX) Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle
Sep 3, 2024 08:03AM Heron Therapeutics (HRTX) Appoints Brett Fleshman as Chief Business Officer
Aug 6, 2024 04:49PM Heron Therapeutics (HRTX) Misses Q2 EPS by 2c, provides guidance